BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Instructions to Upgrade the Mechanical Highlights of Your Shrewd Bed for a Superior Night's Rest - 2Elvis Presley's Infamous Pantera Shooting
- 3Car Investigation: A Survey of \Past the Outside\ Car
- 4Make Your Fantasy Closet: 10 Immortal Design Fundamentals
- 5Can scientists detect life without knowing what it looks like? Research using machine learning offers a new way
- 'Pluribus' release date: Everything you need to know about the new series from 'Better Call Saul's' co-creator
- This Unique National Park In Canada Is Famous For Its Otherworldly Limestone Monoliths
- Insane Realities That Will Make You Reconsider How you might interpret History
- 5 Language Learning Applications
- 10 Natural products to Remember for Your Eating routine for a Better You
- The 10 Most Famous Works of art Ever
- Finding Your Motivation: Moves toward a Satisfying Life
- Global measles cases drop 71% in 24 years as vaccination coverage improves, WHO says
- Instructions to Keep up with Your Traded Teeth for Life span
